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http://dxBackground:We previously performed a trial of intravenous landiolol hydrochloride during and after cardiac
surgery (the PASCAL trial) and demonstrated a preventive effect on postoperative atrial fibrillation (AF). In the
present study, we investigated the efficacy of increasing the dose and administration period of landiolol for pre-
vention of postoperative AF, as well as the effect of oral bisoprolol in the early postoperative period.
Patients andMethods:A total of 105 patients who underwent coronary artery bypass grafting were randomized
to 3 groups: a group receiving intravenous landiolol perioperatively at 5 mg/kg/min for 3 days (group L),
a group receiving oral bisoprolol postoperatively together with landiolol (group LB), and a control group without
beta-blocker therapy (group C). The primary end point was the presence/absence of postoperative AF. Second-
ary end points were (1) the early clinical outcome, (2) hemodynamics, (3) cardiac enzymes (creatine kinase
isoenzyme MB, troponin-I, and human heart fatty acid-binding protein), (4) high-sensitivity C-reactive protein
(hs-CRP) and pentraxin-3, (5) asymmetric dimethylarginine (ADMA), and (6) brain natriuretic peptide.
Results: Postoperative AF occurred in 14.5% of group L, 9.1% of group LB, and 35.3% of group C. A signif-
icant difference was observed between groups LB and C. Significantly higher levels of troponin-I, human heart
fatty acid-binding protein, hs-CRP, pentraxin-3, and ADMAwere noted in group C than in groups L and LB.
Conclusions: Landiolol and bisoprolol prevented postoperative AF. The anti-ischemic, anti-inflammatory, and
anti-oxidant effects of these beta-blockers presumably inhibited the onset of AF. (J Thorac Cardiovasc Surg
2012;144:1241-8)Atrial fibrillation (AF) is the most common complication of
cardiac surgery with a reported incidence of 16% to 85%.1-5
Postoperative AF not only causes problems after surgery
but also has a marked influence on long-term mortality,6-8
so that its prevention important. Several studies on the
prevention of postoperative AF have been reported.5,8-11
According to the American College of Cardiology/
American Heart Association/European Society of
Cardiology (ACC/AHA/ESC) guidelines, there is level A
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Mprophylactic administration being recommended.12 Intrave-
nous infusion of b-blockers has been reported to be more ef-
fective than oral administration, but few randomized
controlled trials have compared these 2 routes of adminis-
tration, probably because intravenous b-blockers are more
likely to cause hypotension and heart failure than
oral b-blockers.13,14 Landiolol is an ultra–short-acting
b-blocker that was developed in Japan and has been used
clinically since 2002. Currently, it is only approved in
Japan. Landiolol has a shorter half-life, higher b1 selectivity,
and weaker negative inotropic effect than other intravenous
b-blockers, so that it is unlikely to cause hypotension.15-17
We18 previously performed an international randomized
controlled trial (Prevention of Atrial Fibrillation in Patients
Having Cardiac Surgery With Landiolol Hydrochloride
[PASCAL]) that investigated whether or not landiolol could
prevent postoperative AF. Intravenous infusion of landiolol
for 2 days at 2 mg/kg/min was compared with placebo,
showing no adverse effects on hemodynamics and signifi-
cant reduction of postoperative AF (10% in the landiolol
group vs 34% in the placebo group). Thus, we confirmed
that landiolol could be administered safety both during
and after cardiac surgery with a preventive effect on postop-
erative AF. The present study (Effect of Beta-Blockers for
Prophylaxis of Atrial Fibrillation After Coronary Artery
Bypass GraftingWith Intravenous Landiolol Hydrochloridediovascular Surgery c Volume 144, Number 5 1241
Abbreviations and Acronyms
ACC ¼ American College of Cardiology
ADMA ¼ asymmetric diemthylarginine
AF ¼ atrial fibrillation
AHA ¼ American Heart Association
BABYLON ¼ Effect of Beta-Blockers for
Prophylaxis of Atrial Fibrillation
After Coronary Artery Bypass
Grafting With Intravenous Landiolol
Hydrochloride and Oral Bisoprolol
Administration
BNP ¼ brain natriuretic peptide
BP ¼ blood pressure
CABG ¼ coronary artery bypass grafting
CK-MB ¼ creatine kinase isoenzyme Mb
CPB ¼ cardiopulmonary bypass
ESC ¼ European Society of Cardiology
HR ¼ heart rate
Hs-CRP ¼ high-sensitivity C-reactive protein
ICU ¼ intensive care unit
PASCAL ¼ Prevention of Atrial Fibrillation in
Patients Having Cardiac Surgery
With Landiolol Hydrochloride
PTX-3 ¼ pentraxin-3
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Mand Oral Bisoprolol Administration [BABYLON] trial) was
undertaken to determine whether or not a higher dose and
longer infusion of landiolol, aswell as adding oral bisoprolol
in the early postoperative period, could more effectively
prevent AF after cardiac surgery.
PATIENTS AND METHODS
Study Protocol
Landiolol has been approved by the Japanese Ministry of Health, Labor
and Welfare for the treatment of postoperative tachyarrhythmias, but its
prophylactic use is still not approved, whereas bisoprolol is approved
only for treating hypertension and heart failure in Japan. Therefore, the
Ethics Committee of Nihon University School of Medicine Itabashi Hospi-
tal assessed and approved this study. We orally explained the details of the
study using materials prepared by the ethics committee to all patients who
were scheduled for coronary artery bypass grafting (CABG) under cardio-
pulmonary bypass (CPB), as well as to their families, and obtained written
informed consent from the subjects. This studywas registered with the Uni-
versity Hospital Medical Information Network (UMIN) (study ID:
UMIN000002489).
The subjects were patients who underwent CABG under CPB after giv-
ing informed consent. Patients were randomized into 3 groups by the lot-
tery method. One group was administered 5 mg/kg/min of landiolol
(Ono Pharmaceutical Co, Ltd, Osaka, Japan) intravenously for 3 days,
starting from the completion of central anastomosis (group L). The second
group was administered landiolol by the same regimen as well as oral or
gavage administration of bisoprolol (2.5mg/day) from the day after surgery
(group LB). The third group did not receive b-blocker therapy (group C).
Intravenous administration of landiolol and placebo was done under
double-blind conditions, and the medical staff and study assistants were1242 The Journal of Thoracic and Cardiovascular Sursingle blinded for oral administration. Right atrial pacing was initiated
when the heart rate (HR) was 90 beats/min or less, and it was discontinued
after 72 hours. CABGwas done under CPBwith a Jostra HL-20 (Jostra Inc,
Hirrlingen, Germany). Nonpulsatlie perfusion was used with hypothermia
(rectal temperature, 34C). Intermittent aortic crossclamping was per-
formed without any cardioplegic solution. In all patients, the left internal
thoracic artery was anastomosed to the left anterior descending branch of
the left coronary artery, while radial artery or saphenous vein grafts were
used at other sites. Exclusion criteria for this study were cardiogenic shock,
sinus bradycardia (50 beats/min at rest), second- or third-degree atrioven-
tricular block, hypothyroidism or hyperthyroidism, arrhythmias, and off-
pump surgery.
On the basis of the results of the PASCAL trial, we planned to enroll 200
patients (at least 60 in each group) to achieve sufficient statistical power for
the primary end point. Use of b-blockers for the prevention of postoperative
AF is recommended by the ACC/AHA/ESC guidelines. However, the effi-
cacy of landiolol for postoperative AF has not been investigated in coun-
tries other than Japan. Therefore, it was decided that if a significant
difference in the incidence of AF or complications was detected by a pilot
study enrolling 100 patients, the ethics committee would examine whether
the study should be continued or not.
End Points
The primary end point was the presence or absence of AF within 1 week
after surgery. The secondary end points were (1) operative mortality and
complications; (2) systolic and diastolic blood pressure (BP) and HR; (3)
creatine kinase isoenzyme Mb (CK-MB) (in the intensive care unit
[ICU] recovery room, after 3 hours in the recovery room, on postoperative
day 1, and on day 3), troponin-I, and human heart fatty acid binding protein
(in the ICU recovery room, and on postoperative days 1 and 3) as bio-
markers of ischemia–reperfusion injury; (4) high-sensitivity C-reactive
protein (hs-CRP) (preoperatively, on postoperative days 1 and 3, weeks 1
and 2, and months 1 and 3), and pentraxin-3 (PTX-3) (preoperatively, in
the ICU recovery room, on postoperative days 1 and 3, and week 1) as bio-
markers of inflammation; (5) asymmetric diemthylarginine (ADMA) (pre-
operatively, in the ICU recovery room, on postoperative days 1 and 3, and
week 1) as a biomarker of oxidative stress; and (6) brain natriuretic peptide
(BNP) (preoperatively, on postoperative days 1 and 3, weeks 1 and 2, and
months 1 and 3). Blood samples for the measurement of PTX-3 and ADMA
were freeze-dried, with PTX-3 being assayed by enzyme-linked immuno-
sorbent assay and ADMA being measured by high-performance liquid
chromatography. Until 72 hours postoperatively, rapid atrial pacing at 90
beats/min was performed when the HR was less than 90 beats/min. In pa-
tients receiving atrial pacing, BP and HR were measured after pacing was
stopped temporarily.
HRwasmonitored continuously for 1week postoperatively and the pres-
ence or absence of AFwas observed. AFwas defined as being present if this
arrhythmia persisted formore than 5minutes or affected hemodynamics and
required treatment. Antiarrhythmic agents and digitalis were not adminis-
tered at the resumption of postoperative oral drug therapy, but administra-
tion was commenced if arrhythmic episodes occurred during the
postoperative period. Postoperative complications were classified as central
nervous systemdisorders, circulatory disorders (lowoutput syndrome, heart
failure, perioperative myocardial infarction, and refractory arrhythmia),
respiratory failure, acute renal failure (requiring dialysis), gastrointestinal
disorders (eg, bleeding, ileus, and hepatic dysfunction requiring hyperali-
mentation), infections (eg, septicemia, pneumonia, and mediastinitis),
and other disorders requiring long-term management in the ICU.
Statistical Analysis
Results are expressed as the mean standard deviation. For parametric
and nonparametric data, the significance of differences was determined by
using the Student t test and Fisher’s exact test, respectively. Other data were
analyzed by repeated-measures analysis of variance, with a post-hocgery c November 2012
TABLE 1. Comparison of clinical characteristics and measured data
L group LB group C group
P
value
No. 34 33 34
Age (y) 68.5  9.6 68.1  8.2 68.2  7.5 .9742
80 y< 3 2 2 1.00
75 y< 8 9 6 .6380
70 y< 16 16 14 .9073
Gender (male/female) 26:8 26:7 30:4 .4811
Body surface area (m2) 1.67  0.15 1.63  0.17 1.66  0.14 .6215
EuroSCORE 7.2  3.4 6.1  3.3 6.1  3.8 .3437
EuroSCORE>8 15 13 7 .0972
EuroSCORE>10 8 4 7 .5302
Diagnosis
Acute myocardial
infarction
3 2 1 .7567
Old myocardial
infarction
9 14 12
Unstable angina 17 13 14
Stable angina 5 4 7
Emergency surgery 14 7 7 .1309
Risk factors
Diabetes mellitus 16 19 14 .4309
Hypertension 26 26 28 .8681
Hyperlipidemia 17 12 17 .4348
Obesity 7 6 5 .8543
Smoking 13 11 13 .9012
COPD 2 1 2 1.00
Cerebrovascular
disease
3 3 1 .6254
Chronic renal failure 8 13 16 .1148
Hemodialysis 4 5 6 .8353
Oral medications
ARB 16 15 18 .9036
ACE-I 3 5 1 .1861
Ca antagonist 11 13 15 .6049
Beta-blocker 9 7 9 .8785
Aldosterone blocker 1 3 2 .5245
Statin 14 14 16 .9065
Ejection fraction (%) 60.4  10.1 53.9  14.5 60.0  13.6 .0780
COPD,Chronic obstructive pulmonary disease; ARB, angiotensin II receptor blocker;
ACE-I, angiotensin-converting enzyme inhibitor; Ca, calcium.
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MScheffe test. All analyses were conducted with SPSS software (SPSS Inc,
Chicago, Ill).
RESULTS
Subject Disposition
A total of 105 patients were enrolled. Four patients were
excluded because they had off-pump CABG or underwent
another cardiac operation concomitantly, after which 34
were assigned to group L, 33 to group LB, and 34 to group
C. Treatment was not discontinued because of hypotension
or bradycardia in patients from any of the groups, and the
trial was completed by all subjects.
Baseline Characteristics
The baseline characteristics are shown in Table 1. There
were no significant differences among the 3 groups with
respect to age, sex, body surface area, EuroSCORE, diagno-
sis, emergency surgery, risk factors, complications, preop-
erative oral medications, ejection fraction, BNP, systolic
and diastolic BP, HR, hs-CRP, ADMA, and PTX-3
(Table 1 and Figures 1-4).
Intraoperative and Postoperative Parameters
No significant differences among the 3 groups were
noted with respect to the aortic perfusion time, extracor-
poreal circulation time, number of bypasses, number
of doses of catecholamines, postoperative oral medica-
tions, ejection fraction obtained by echocardiography at
1 week postoperatively, and days of hospitalization
(Table 2).
Primary End Point
Postoperative AF was detected in 5 (14.7%) patients
from group L, 3 (9.1%) patients from group LB, and 12
(35.3%) patients from group C. There were no significant
differences between group L and the other 2 groups, but
group LB showed a significantly lower incidence of AF
than group C (P ¼ .017). The timing of the onset of AF
did not differ among the 3 groups (P¼ .2445). Also, the in-
cidence of AF within 3 days after discontinuing intravenous
landiolol or placebo (physiologic saline) showed no signif-
icant difference (P ¼ .552), with the rate being 60% in
group L, 75% in group LB, and 33.3% in group C.
Secondary End Points
Death and complications. Postoperative death (Table 2)
occurred in 1 patient from group L (mediastinitis) and 1 pa-
tient from group C (arrhythmia), and there was no signifi-
cant difference in the death rate among the 3 groups
(P ¼ 1.00). Postoperative complications affected 2 patients
from group L (myocardial infarction and mediastinitis in 1
case each), 2 patients from group LB (perioperative myo-
cardial infarction and acute renal failure in 1 case each),
and 3 patients from group C (low-output syndrome, heartThe Journal of Thoracic and Carfailure, and arrhythmia in 1 case each). There were no sig-
nificant differences of complications among the 3 groups
(P ¼ 1.00).
Hemodynamics. No significant differences of preopera-
tive systolic and diastolic BP and HR were observed among
the 3 groups (Figure 1). There were also no differences of
BP among the 3 groups during the postoperative course.
Postoperative pacing was done for 28 patients in group L,
27 in group LB, and 23 in group C, with no significant dif-
ference among the 3 groups (P ¼ .2898). On postoperative
days 0 to 4, the HR showed no significant differences when
groups L and LB were compared with group C. On postop-
erative day 7, however, group LB had a significantly lower
HR than groups L and C (P ¼ .002).diovascular Surgery c Volume 144, Number 5 1243
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FIGURE 1. Hemodynamic profile (systolic and diastolic blood pressure
[upper] and heart rate [lower]). No significant differences in systolic and
diastolic blood pressure were found among the groups, but heart rate was
significantly lower in the L group and LB group than in the C group
from postoperative day 0 to day 4. On postoperative day 7, the value was
significantly lower in the LB group than in the L group and C group.
sBP, Systolic blood pressure; dBP, diastolic blood pressure; HR, heart
rate; n.s., not significant.
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MBiomarkers of myocardial ischemia. On postoperative
day 2, (Figure 2) group L had a significantly lower CK-
MB level than group C (P¼ .0359). On postoperative day 3,
groups L and LB both had significantly lower CK-MB
levels than group C (group L vs group C, P ¼ .0059; group
LB vs group C, P ¼ .0475). Troponin-I showed significant
differences among the 3 groups in the ICU recovery room
(P ¼ .0103), with groups L and LB having significantly
lower values than group C (group L vs group C,
P¼ .0166; group LB vs group C, P¼ .005). In the recovery
room, groups L and LB had significantly lower human heart
fatty acid binding protein levels than group C (group L vs
group C, P ¼ .0246; group LB vs group C, P ¼ .0216).
On postoperative day 1, groups L and LB also had signifi-
cantly lower values than group C (group L vs group C,
P ¼ .001; group LB vs group C, P ¼ .038).
Biomarkers of inflammation. Preoperative values of
these biomarkers did not show any significant differences
among the 3 groups (Figure 3). On postoperative day 3,
group L and group LB had significantly lower hs-CRP
levels than group C (group L vs group C, P ¼ .0155; group
LB vs group C, P¼ .0134). In postoperative week 1, groups
L and LB also showed significantly lower values than group
C (group L vs group C, P ¼ .0051; group LB vs group C,1244 The Journal of Thoracic and Cardiovascular SurP ¼ .0003). In postoperative week 2, however, group LB
had a significantly lower value than groups L or C (group
LB vs group L, P ¼ .0248; group LB vs group C,
P ¼ .0039). On postoperative day 1, groups L and LB had
significantly lower PTX-3 levels than group C (group L
vs group C, P ¼ .0001; group LB vs group C, P ¼ .0001),
and group LB also had a significantly lower value than
group L (group LB vs group L, P ¼ .0009). On postopera-
tive day 3, groups L and LB again showed significantly
lower values than group C (group L vs group C,
P ¼ .0001; group LB vs group C, P< .0001), and group
LB also had a significantly lower value than group L (group
LB vs group L, P¼ .0449). In postoperative week 1, groups
L and LB once again had significantly lower PTX-3 levels
than group C (group L vs group C, P< .0001; group LB
vs group C,P<.0001), while group LB group also had a sig-
nificantly lower value than group L (group LB vs group L,
P ¼ .0135).
Biomarker of oxidative stress. On postoperative day 3,
(Figure 3) groups L and LB had significantly lower
ADMA levels than group C (group L vs group C,
P ¼ .0289; group LB vs group C, P< .0001), and group
LB also had a significantly lower value than group L (group
LB vs group L, P ¼ .0138). In week 1, groups L and LB
again showed significantly lower values than group C
(group L vs group C, P< .0001; group LB vs group C,
P<.0001).
BNP. Preoperative BNP levels showed no significant
differences among the 3 groups (Figure 4). On postopera-
tive day 1, month 1, and month 3, groups L and LB had
significantly lower BNP values than group C (P<.0001),
but there were no differences between groups L and LB.
When these results were presented to the ethics com-
mittee, although there are no guidelines regarding the
prevention of postoperative AF in Japan, continuation
of this trial was judged to be ethically problematic and
it was stopped because there was a significant difference
in the incidnece of AF between group C (n ¼ 34) and
group LB (n ¼ 75) (35.3% vs 9.1%; P ¼ .00339), while
there was no difference of adverse events among the 3
groups.
DISCUSSION
The preventive effect of landiolol on AF after CABGwas
similar in this study and the previous PASCAL trial. AF oc-
curred in 10% of patients treated with landiolol in the PAS-
CAL trial,18 and the onset was almost always after landiolol
had been discontinued, suggesting that postoperative AF
might have been prevented if the dose of landiolol had
been increased or the administration period had been pro-
longed. Therefore, the present study was performed as
a continuation of the PASCAL trial. However, we found
that the incidence of AF in the landiolol monotherapy group
(group L) was 14% and there was no evidence thatgery c November 2012
FIGURE 2. Changes in ischemic biomarker data: creatine kinase isoenzyme Mb (CK-MB) on postoperative days 2 and 3, troponin-I in the intensive care
unit (ICU) recovery room and human heart fatty acid binding protein (H-FABP) in the ICU recovery room and on postoperative day 1 were significantly
lower in the L group and LB group than in the C group.
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Mincreasing the dose of landiolol and extending its adminis-
tration period improved the prevention of AF. In the 2
groups treated with landiolol, the incidence of AF after dis-
continuation of the drug was 50% for group L and 75% for
group LB, with both rates being higher than that of 33.3%
in group C. Therefore, it appears that the occurrence of AF
was prevented during infusion of landiolol. Because of the
influence of various factors such as old age, cardiac func-
tion, chronic obstructive pulmonary disease, and left atrial
diameter, postoperative AF cannot always be prevented
by b-blockers. However, it appears that the anti-ischemic,
anti-inflammatory, and antioxidant actions of b-blockers
may inhibit AF based on our data regarding various bio-
markers and HR. In group LB, hs-CRP in postoperative
week 2, PTX-3 on postoperative day 1, day 3, and week 1,
and ADMA on postoperative day 3 and week 1 were
all significantly lower than in the other 2 groups. Also,
the BNP level on postoperative day 1, month 1, and month
3 was significantly higher in group C than in the other 2
groups. From our results, landiolol inhibits AF during sur-
gery and in the early postoperative period, whereas early
postoperative initiation of oral b-blocker therapy and con-
tinuation of oral therapy seems to be more important than
increasing the dose of landiolol or extending its duration
of administration.
When the protocol for this study was being drafted,
selection of the oral b-blocker was a major problem. It hasThe Journal of Thoracic and Carbeen shown that b-blockers reduce cardiac events in vari-
ous large-scale studies of patients with acute myocardial
infarction or chronic heart failure, and b-blockers without
intrinsic sympathomimetic activity as well as lipid-soluble
drugs have been recommended.19 In this study, we used bi-
soprolol as the oral b-blocker, inasmuch as it lacks intrinsic
sympathomimetic activity, shows high lipophilicity, and
has high b1 selectivity similar to landiolol. In a comparative
study of bisoprolol and carvedilol for congestive heart fail-
ure, Konishi and associates20 found no difference between
the 2 drugs with respect to the cardiac event-free rate, but
AF was significantly less frequent and BNP was lower in
the bisoprolol group. Among the few studies that have as-
sessed the effect of oral b-blockers on postoperative AF,
some reports have appeared recently. When they compared
bisoprolol and carvedilol in patients with cardiac dysfunc-
tion undergoing CABG, Marazzi and associates21 found
that the bisoprolol group had a significantly lower HR
than the carvedilol group. They also found that the inci-
dence of postoperative AF was lower in the bisoprolol
group. In a comparative study of bisoprolol and amiodar-
one, which is known to be effective for prevention of post-
operative AF together with b-blockers, Sleilaty and
colleagues22 detected AF in 12.7% of the bisoprolol group
versus 15.3% of the amiodarone group, and the maximal
ventricular rate was also lower in the bisoprolol group. In
the present study, landiolol was infused perioperativelydiovascular Surgery c Volume 144, Number 5 1245
FIGURE 3. Changes in inflammation biomarkers and oxidative stress biomarkers>high-sensitive C-reactive protein (hs-CRP) was significantly lower in
the L group and LB group than in the C group at postoperative day 3, week 1, and week 2. In postoperativeweek 2, the value in the LB groupwas significantly
lower than those in the L group and C group. Pentraxin-3 (PTX-3) was significantly lower in the L group and LB group than in the C group at postoperative
day 1, day 3, and week 1. It was also significantly lower in the LB group than in the L group. Asymmetric dimethylarginine (ADMA) was significantly lower
in the L group and LB group than in the C group at postoperative day 3 and week 1 and also significantly lower in the LB group than in the L group in
postoperative week 1.
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Mand we then continued treatment with oral bisoprolol,
a highly selective b1 receptor antagonist like landiolol, in
group LB. There were no problems such as hypotension,
bradycardia, or asthma, and no other safety problems
were noted, whereas a marked prophylactic effect on post-
operative AF was achieved.FIGURE 4. Changes in brain natriuertic peptide (BNP). BNP was signif-
icantly lower in the L group and LB group than in the C group at postop-
erative day 1, month 1, and month 3.
1246 The Journal of Thoracic and Cardiovascular SurIn this study, we analyzed PTX-3 as a marker of acute in-
flammation and measured ADMA as a biomarker for vascu-
lar endothelial function and oxidative stress. PTX-3 has
been reported as a new biomarker for the severity and prog-
nosis of acute myocardial infarction and heart failure.23,24 It
has been reported that ADMA increases when endothelial
function is impaired and serves as a marker for predicting
cardiovascular events and AF.25,26 In the present study,
the data for these biomarkers demonstrated an anti-
inflammatory and antioxidant effect of b-blocker therapy.
However, the clinical significance of these biomarkers is
yet to be fully clarified, so further investigations will be
needed.
The present findings and the results of the PASCAL trial
suggest that landiolol may be a safe intravenous b-blocker
for perioperative use with little risk of hypotension, which
is a problem with existing treatment, but this study was
not sufficiently powered to determine safety. Perioperative
b-blocker therapy using landiolol and bisoprolol may
prevent early postoperative AF owing to the anti-
inflammatory, anti-ischemic, and antioxidant effects of
these drugs. Prophylactic administration of b-blockers is al-
ready recommended, and combining landiolol with an oral
b-blocker may further reduce the incidence of postoperative
AF. However, large-scale study would be needed to confirm
the beneficial effect of landiolol.gery c November 2012
TABLE 2. Perioperative and postoperative findings
L group LB group C group
P
value
No. 34 33 34
Days until AF 3.7  1.4 3.0  1.4 2.5  1.3 .2445
Mortality 1 0 1 1.00
Complications 2 3 3 1.00
No. of bypasses 3.1  0.8 3.4  1.0 3.4  0.9 .1747
ACCT (min) 32.3  9.9 36.4  23.9 33.7  23.5 .4771
ECCT (min) 96.4  27.2 103.1  31.0 102.6  36.5 .6940
Dopanine 10 10 9 .9619
Dobutamine 4 4 4 1.00
Norepinephrine 4 3 3 1.00
Postoperative pacing 28 27 23 .2898
Hospital stay (d) 11.8  6.9 11.1  3.0 12.2  9.0 .8379
Oral medications
ARB 13 17 18 .4457
ACE-I 0 0 0 1.00
Ca antagonist 13 12 19 .2885
Aldosterone
blocker
26 27 26 .5689
Statin 23 26 25 .8681
Ejection fraction (%) 61.3  14.3 58.0  12.9 57.1  12.8 .4096
AF, Atrial fibrillation; ACCT, aortic crossclamping time; ECCT, extracorporeal circu-
lation time; ARB, angiotensin II receptor blocker; ACE-I, angiotensin-converting en-
zyme inhibitor; Ca, calcium.
Sezai et al Perioperative Management
P
MLimitations
The present study was single blind because use of
landiolol was blinded, but there was no placebo for biso-
prolol (only the medical and measurement staff were
blinded).
On the basis of the results of the PASCAL trial, the power
of test for postoperative AF was calculated, revealing that
60 patients or more per group were required. Accordingly,
this study was designed to enroll 200 patients. However, af-
ter conducting an interim analysis of the initial 100 patients
and submitting the results to the ethics committee, it was de-
cided that the study should be terminated because of the
very high incidence of AF in the placebo group. It is likely
that statistically reliable data would have been obtained if
we had been able to analyze 200 patients, but the truncated
study did not yield sufficiently reliable results. Despite this,
comparison of 2 active drug groups in the future should al-
low clarification of the effectiveness of oral and intravenous
b-blockers for preventing postoperative AF, as well as the
best protocol for switching to oral b-blockers. Another
problem was that 25% of the subjects were using
b-blockers preoperatively. Although there was no differ-
ence in preoperative use among the 3 groups, postoperative
discontinuation of b-blocker therapy might have had an ef-
fect on the incidence of postoperative AF. Accordingly,
a study of patients without preoperative b-blocker therapy
should be done in the future. Moreover, our single-center
design made it difficult to obtain sufficient patients, andThe Journal of Thoracic and Cara large-scale multicenter study is needed to obtain more
meaningful results.References
1. Villareal RP, Hariharan R, Liu BC, Kar B, Lee V, Elayda M, et al. Postoperative
atrial fibrillation and mortality after coronary atrial bypass surgery. J Am Col
Cardiol. 2004;43:742-8.
2. Shen J, Shelly L, Zheng V, Buckley P, Damiano RJ, Schuessler RB. The
persistent problem of new-onset postoperative atrial fibrillation: a single-
institution experience over two decades. J Thorac Cardiovasc Surg. 2011;141:
559-70.
3. Sezai A, Hata M, Niino T, Kasamaki Y, Nakai T, Hirayama A, et al. Study of the
factors related to atrial fibrillation after coronary artery bypass grafting: a search
for a marker to predict the occurrence of atrial fibrillation before surgical inter-
vention. J Thorac Cardiovasc Surg. 2009;137:895-900.
4. Nakai T, Lee RJ, Schiller NB, Bellows, Dzankic S, Reeves JR, et al. The relative
importance of left atrial function versus dimension in predicting atrial fibrillation
after coronary artery bypass graft surgery. Am Heart J. 2002;143:181-6.
5. Budeus M, Hennersdorf M, Perings S, Roehlen S, Schnitzler S, Felix O, et al.
Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary
bypass grafting: a prospective, double-blind, placebo-controlled, randomized
study. Eur Heart J. 2006;27:1584-91.
6. Bramer S, van Stranten AHM, Hamad MAS, Berrlkouw E, Martens EJ,
Maessen JG. The impact of new-onset postoperative atrial fibrillation on
mortality after coronary artery bypass grafting. Ann Thorac Surg. 2010;90:
443-50.
7. El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, et al.
New-onset atrial fibrillation predicts long-term mortality after coronary artery
bypass graft. J Am Coll Cardiol. 2010;55:1370-6.
8. KawR, Hernandez AV,Masood I, Gillinov AM, SalibaW, Blackstone EH. Short-
and long-term mortality associated with new-onset atrial fibrillation after coro-
nary artery bypass grafting: a systematic review and meta-analysis. J Thorac
Cardiovasc Surg. 2011;141:1305-12.
9. Giri S, White CM, Dunn AB, Felton K, Freeman-Bosco L, Reddy P, et al. Oral
amiodarone for prevention of atrial fibrillation after open heart surgery, the atrial
fibrillation suppression trial (AFIST): randomized placebo-controlled trial. Lan-
cet. 2001;357:830-6.
10. Shen J, Lall S, Zheng V, Buckley P, Damiano RJ, Schuessler RB. The persistent
problem of new-onset postoperative atrial fibrillation: a single-institution experi-
ence over two decades. J Thorac Cardiovasc Surg. 2011;141:559-70.
11. Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effect of statins on
atrial fibrillation after cardiac surgery: a duration- and dose-response meta-anal-
ysis. J Thorac Cardiovasc Surg. 2010;140:364-72.
12. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al.
ACC/AHA/ESC 2006 guideline for management of patients with atrial fibrilla-
tion: a report of the American College of Cardiology/American Heart Associa-
tion task force on practice guidelines and the European Society of Cardiology
committee for practice guidelines (writing committee to revise the 2001 guide-
lines for the management of patients with atrial fibrillation): developed in collab-
oration with the European Heart Rhythm Association and Heart Rhythm Society.
Circulation. 2006;114:e257-354.
13. Maniar PB, Balcetyye-Harris N, Tamis JE, Steinberg JS. Intravenous versus oral
beta-blockers for prevention of post-CABG atrial fibrillation in high-risk patients
identified by signal-averaged ECG: lessons of a pilot study. Card Electrophysiol
Rev. 2003;7:158-61.
14. Mooss AN, Wurdeman RL, Mohiuddin EM, Reyes AP, Sugimoto JT,
Scott W, et al. Esmolol versus diltiazem in the treatment of postoperative
atrial fibrillation/atrial flutter after open heart surgery. Am Heart J. 2000;
140:176-80.
15. Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, et al.
Development of a highly cardioselective ultra short-acting beta-blocker, ONO-
1101. Chem Pharm Bull (Tokyo). 1992;40:1462-9.
16. Sugiyama A, Takahara A, Hashimoto K. Electrophysiologic cardiohemodynamic
and beta-blocking actions of a new ultra-short-acting beta blocker, ONO-1101,
assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc
Pharmacol. 1999;34:70-7.
17. Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits,
landiolol, a new ultra-short-acting b-blocker, exerts a more potent negative chro-
nologic effect and less effect on blood pressure than esmolol.Can JAnesth. 2001;
48:985-9.diovascular Surgery c Volume 144, Number 5 1247
Perioperative Management Sezai et al
P
M18. Sezai A,Minami K, Nakai T, HataM, Yoshitake I, Wakui S, et al. Landiolol hydro-
chloride forpreventionofatrial fibrillationafter coronary artery bypassgrafting:new
evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141:1478-87.
19. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al.
ACC/AHA 2005 guideline update for the diagnosis and management of chronic
heart failure in the adult: a report of the American College of Cardiology/Amer-
ican Heart Association task force on practice guideline: developed in collabora-
tion with the American College of Chest Physicians and the International Society
for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.
Circulation. 2005;112:e154-235.
20. Konishi M, Haraguchi G, Kimura S, Inagaki H, Kawabata M, Hachiya H,
et al. Comparative effects of carvedilol vs. bisoprolol for severe congestive
heart failure. Circ J. 2010;74:1127-34.
21. Marazzi G, Iellamo F, Volterrani M, Caminiti G, Madonna M, Arisi G, et al.
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of
postdischarge atrial fibrillation after coronary artery bypass grafting in patients
with heart failure. Am J Cardiol. 2011;107:215-9.1248 The Journal of Thoracic and Cardiovascular Sur22. Sleilaty G, Madi-Jebara S, Yazigi A, Haddad F, Hayeck G, El Rassi I, et al. Post-
operative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fi-
brillation after coronary artery bypass graft surgery: a prospective randomized
trial. Int J Cardiol. 2009;137:116-22.
23. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic
significance of the long pentraxin PTX3 in acute myocardial infarction. Circula-
tion. 2004;110:2349-54.
24. Matusbara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pen-
traxin 3 is a new inflammatory marker correlated with left ventricular diastolic
dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol.
2011;57:861-9.
25. Goette A, Hammwoehner M, Bukowska A, Scalera F, Martens-Lobenhoffer J,
Dobrev D, et al. The impact of rapid atrial pacing on ADMA and endothelial
NOS. Int J Cardiol. 2012;26(154):141-6.
26. Xia W, Yin Z, Li J, Song Y, Qu X. Effects of rosuvastatin on asymmetric dime-
thylarginine levels and early atrial fibrillation recurrence after electrical cardio-
version. PACE. 2009;32:1562-6.gery c November 2012
